Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.
Objective: This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…5-year results from the NSTAPS trial: comparing bilateral deep brain stimulation of the globus pallidus pars interna versus the subthalamic nucleus for advanced Parkinson’s disease.
Objective: Comparing motor, cognitive, and psychiatric outcome 5 years after bilateral deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) and the subthalamic…Preliminary Report on the MAESTRO Study: A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease.
Objective: To report enrollment and tolerability data of mirabegron treatment in PD patients with OAB. Background: Lower urinary tract symptoms in PD have an estimated…ON-time evolution following one-year open-label opicapone: BIPARK-I study
Objective: ON-time evolution following 1-year, open-label (OL), once-daily (QD) opicapone (OPC) treatment in patients with Parkinson’s disease (PD) on levodopa-therapy and with motor fluctuations. Background:…Associating patient impression of improvement with efficacy endpoints in Parkinson’s disease: A post-hoc analysis of a tozadenant study
Objective: To evaluate whether patient perceived improvement of Parkinson’s disease (PD) symptoms was associated with improvement in efficacy endpoints (mean daily OFF time and ON…Cardiac 123I-MIBG Scintigraphy, olfactory testing and transcranial sonography for differentiating between Parkinson’s disease and atypical parkinsonian syndromes during the early stage
Objective: To evaluate the utility of the combined use of cardiac metaiodobenzylguanidine (MIBG) scintigraphy, olfactory testing, and substantia nigra (SN) hyperechogenicity on transcranial sonography (TCS)…Post-movement beta rebound inhibits future movement
Objective: To evaluate the potential inhibitory effect of post-movement beta rebound (PMBR) on future movement production. Background: Changes in the cortical power of beta oscillations within the…Structural brain abnormalities associated with preclinical cognitive impairment in Idiopathic Parkinson’s Disease.
Objective: Using the Progressive Parkinson’s Initiative (PPMI) data, clinical and structural differences between individuals destined to develop PD cognitive impairment was defined. Background: Cognitive dysfunction…Multicenter Validation of Disease- related Parkinson’s disease pattern with Resting State functional MRI
Objective: To validate Parkinson’s Disease-related network topography characterized with resting-state functional MRI (rs-fMRI) in two multicenter based cohorts of idiopathic Parkinson’s disease (IPD) patients. Background:…In vivo mapping of nigro-striatal dopamine transporter (DAT) availability in early Parkinson´s disease patients using [18F]FE-PE2I and high-resolution positron emission tomography.
Objective: The objective of the present work was to evaluate in vivo with high resolution positron emission tomography (PET), the relative loss of the dopamine…
- « Previous Page
- 1
- …
- 99
- 100
- 101
- 102
- 103
- …
- 155
- Next Page »